Ramifications way beyond financial loss and breach of privacy? Equip Global proudly presents Cyber Security for Healthcare – a live online event from 6 – 9 October 2020. This masterclass will emphasize developing effective policies and strategies to counter cyber threats of various kinds, developing an effective security architecture and infrastructure, and improving cyber and cyber physical security risk management Learning outcome
Understand the different types of cyber security breaches that can occur including browser-based attacks, phishing attacks, malware, ransomware attacks, data breaches, DDOs attacks amongst others and how you can combat them
Gain insights on cyber security for connected medical devices
Learn how to ensure your security infrastructure is strengthened
Join us for our 4-day case-study-driven and practical cyber security for healthcare masterclass. Learn from the expert trainer how you can develop a fool proof and effective cyber security strategy that protects your organization, operations, your patients’ privacy and public security whilst ensuring your healthcare services and patients’ health are not compromised. Equip Global Equip Global provides business executives globally with practical and tailored industry conferences, in-house and corporate training courses that focus on offering solutions that have met the concrete test of application and have proven to improve an organization’s productivity and performance. Equip Global conferences and training courses will equip you with practical knowledge and valuable connections that drive tangible and sustainable bottom-line results in your business. Event website:https://www.equip-global.com/cyber-security-for-healthcare-masterclass-live-online
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:30Cyber security for healthcare – your must attend masterclass
Scientists at Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA have identified 30 existing drugs that stop the replication of SARS-CoV-2, the virus that causes Covid-19. Almost all of the drugs are entirely different from those currently being tested in clinical trials, and weren’t previously known to hold promise for Covid-19 treatment. The new candidates expand the number of “shots on goal” for a potential Covid-19 treatment and could reach patients faster than drugs that are created from scratch. The study was placed on bioRxiv – https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1 – an open-access distribution service for preprints of life science research.
“We believe this is one of the first comprehensive drug screens using the live SARS-CoV-2 virus, and our hope is that one or more of these drugs will save lives while we wait for a vaccine for Covid-19,” said Sumit Chanda, Ph.D., director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and senior author of the study. “Many drugs identified in this study – most of which are new to the Covid-19 research community – can begin clinical trials immediately or in a few months after additional testing.”
The drugs were identified by screening more than 12,000 drugs from the ReFRAME drug repurposing collection – a library of existing drugs that have been approved by the FDA for other diseases or have been tested extensively for human safety. ReFRAME was created by Scripps Research with support from the Bill & Melinda Gates Foundation to accelerate efforts to fight deadly diseases. Every compound was tested against the live SARS-CoV-2 virus, isolated from patients in Washington State and China, and the final 30 drugs were selected based on their ability to stop the virus’s growth.
“For us, the starting point for finding any new antiviral drug is to measure its ability to block viral replication in the lab,” says Chanda. “Since the drugs we identified in this study have already been tested in humans and proven safe, we can leapfrog over the more than half decade of studies normally required to get approval for human use.”
Highlights of the scientists’ discoveries follow. Each drug or experimental compound requires further evaluation in clinical trials to prove its effectiveness in treating people with Covid-19 before it can be used broadly.
27 drugs that are not currently under evaluation for Covid-19 were effective at halting viral replication. 17 of these drugs have an extensive record of human safety from clinical studies in non-Covid-19 diseases, including four—clofazimine, acitretin, tretinoin and astemizole—that were previously approved by the FDA for other indications.
Thus far, six of the 17 were shown to be effective at concentrations, or doses, likely to be effective and tolerable in humans. Four of these six drugs – apilimod, MLN-3897, VBY-828 and ONO 5334 – have been tested clinically for diseases including rheumatoid arthritis, Crohn’s disease, osteoporosis and cancer.
In addition to the 27 drug candidates, three drugs currently in clinical trials for Covid-19, including remdesivir and chloroquine derivatives, were also shown to be effective at stopping the growth of SARS-CoV-2. These results reaffirm their promise as potential Covid-19 treatments and support the continuation of ongoing clinical trials to prove their effectiveness in patients.
Depending on regulatory guidance, the newly identified drug candidates may proceed directly to Covid-19 clinical trials or undergo further testing for efficacy in animal models.
“Based on the extensive data in this study, we believe the four drugs described above—apilimod, MLN-3897, VBY-825 and ONO 5334 – represent the best new approaches for a near-term Covid-19 treatment,” says Chanda. “However, we believe that all 30 drug candidates should be fully explored, as they were clearly active and effective at halting viral replication in our tests.”
“We have chosen to release these findings to the scientific and medical community now to help address the current global health emergency,” Chanda continues. “The data from this drug screen is a treasure trove; and we will continue to mine the data from this analysis, with a goal to find additional candidate therapies – and combinations of drugs – as they are identified.”
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:33Researchers use live virus to identify 30 existing drugs that could treat Covid-19
A new study by Chinese researchers to check aerosol and surface distribution of SARS-COV-2 in an Intensive Care Unit (ICU) and General Ward (GW) with COVID-19 infected patients found that the virus can be detected in the air up to 4 metres away from patients. In addition, they found the virus was widely distributed on floors and recommend that persons disinfect shoe soles before walking out of wards containing COVID-19 patients.
They also found the virus on computer mice, trash cans, and sickbed handrails.
The early release study was published April 10 in Emerging Infectious Diseases.
The aerosol distribution of the virus has been controversial with previous findings based on very small studies which may not reflect real conditions in a hospital at full capacity. This new study, however, tested surface and air samples in a busy hospital in Wuhan from February 19 through March 2 at the height of outbreak in that city.
The study is particularly pertinent for healthcare workers treating COVID-19 patients and offers a number of conclusions and recommendations.
SARS-CoV-2 was widely distributed in the air and on object surfaces in both the ICU and GW, implying a potentially high infection risk for medical staff and other close contacts.
The SARS-CoV-2 aerosol distribution characteristics in the GW indicate that the transmission distance of SARS-CoV-2 might be 4 metres.
The environmental contamination was greater in the ICU than in the GW; thus, stricter protective measures should be taken by medical staff working in the ICU.
They also found that as the virus settles on the floor it could be tracked around the hospital where healthcare workers from the ICU and GW had walked, such as the floor of the pharmacy.
On this evidence the authors highly recommend that persons disinfect shoe soles before walking out of wards containing COVID-19 patients.
The researchers note that as of March 30 no healthworkers at the hospital had become infected and point out that appropriate precautions can effectively prevent infection.
The authors note that the results of their nucleic acid test do not indicate the amount of viable virus. And that because the minimal infectious dose is unknown, the aerosol transmission distance cannot be strictly determined. doi: 10.3201/eid2607.200885
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:37Study shows SARS-COV-2 can be carried in aerosol up to 4 metres from infected person
Starna, established 1964, has a worldwide reputation for quality, service and innovation in the production and supply of spectrophotometer cells, optical components and Certified Reference Materials (CRMs). World-leader with over 50 years’ experience in the production of Certified Reference Materials for UV-Vis-NIR & Fluorescence spectroscopy; it is the only company to achieve both ISO/IEC 17025 and ISO 17034 for this range of products. A highly regarded manufacturer of high precision quartz and glass Cells/Cuvettes for Photometers and Fluorimeters. Starna sells worldwide to instrument manufacturers, pharmaceuti- cals, life-biosciences, R&D laboratories, medical companies and universities.
www.starna.comBooth # 1G11-2
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:40Starna Scientific at Medica
Philips and B. Braun, a player in regional anesthesia and pain management, recently announced the launch of Onvision, a breakthrough ultrasound guidance solution for real-time needle tip tracking in regional anesthesia. Available on the latest version of the B. Braun and Philips Xperius ultrasound system, Onvision gives anesthesiologists the confidence to accurately position the needle tip inside the body. The introduction is part of a multi-year strategic alliance between Philips and B. Braun to innovate in ultrasound-guided regional anesthesia, a rapidly growing alternative to general anesthesia. Accurate needle placement is critical to the success of regional anesthesia procedures, such as peripheral nerve blocks, both in terms of effective pain relief and the avoidance of unintended nerve and vessel punctures or collateral damage to surrounding tissue. While real-time ultrasound imaging has proved to be a valuable tool for needle guidance, failure to optimally visualize the needle tip remains a challenge for both novice and experienced anesthetists. Currently, 10-20% of all peripheral nerve blocks are ineffective on the first attempt. By simplifying alignment between the needle and ultrasound probe, Onvision reduces the effort needed to interpret the ultrasound image. This allows the anesthesiologist to more confidently guide the tip of the needle to its target. “Regional anesthesia is a rapidly growing alternative to general anesthesia and has the potential to improve patient outcomes as well as increase workflow efficiency in the hospital,” said Bert van Meurs, Chief Business Leader, Image Guided Therapy at Royal Philips. “By combining B. Braun’s expertise in needle design with Philips’ capabilities in real-time image guidance, we’ve created a solution to one of the biggest challenges in regional anesthesia – accurate positioning of the needle tip in the body. Our alliance with B. Braun is a strong example of our commitment to partner with industry leaders to grow our footprint in the therapy market.” “Our customers want intuitive solutions that allow them to focus on the patient rather than the technology, so they can achieve the best outcomes. As demand for regional anesthesia grows, improved efficiency can also help reduce the pressure of an increasing workload,” said Dr. Meinrad Lugan, Member of the Board for the Hospital Care Division at B. Braun. “Onvision is a perfect example of what can be achieved through shared expertise to meet the evolving needs of our customers, bringing regional anesthesia to more patients in more hospitals worldwide.” Together, B. Braun’s Stimuplex Onvision needles and Philips’ Onvision needle tip tracking technology indicate the position of the needle tip in relation to the ultrasound viewing plane to an accuracy of better than 3mm. A sensitive micro-sensor placed on the needle, combined with advanced signal processing and visualization techniques on the Xperius system, indicate the real-time location of the needle tip in relation to the 2D ultrasound viewing plane. The solution provides greater flexibility in needle trajectory and can reduce procedure times. The increased confidence and predictability offered by Xperius and Onvision will empower more anesthesiologists to embrace regional anesthesia as a viable and effective alternative to general anesthesia. Regional anesthesia or analgesia involves the injection of an anesthetic in the proximity of a nerve, targeting areas of a patient’s body that are subject to surgical intervention. Regional anesthesia can have significant advantages over general anesthesia for both patients and hospitals. Patients undergoing regional anesthesia typically benefit from reduced opioid consumption and fewer side-effects, such as nausea. Moreover, regional anesthesia may lead to faster post-surgical recovery, allowing patients to ambulate or leave the hospital sooner, which benefits both patients and hospitals. Together, Xperius and Onvision form an integrated point-of-care solution for supporting current and future needs in regional anesthesia. They are co-branded and sold via B. Braun’s global sales network, with Philips providing installation and service. Xperius is part of Philips’ portfolio of point-of-care ultrasound systems, which offers clinicians the ability to diagnose and care for their patients in any work environment.
www.philips.com
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:44Philips and B. Braun launch needle tip tracking for real-time ultrasound guidance for regional anesthesia
Scientists at the Center for Cardiology of the Mainz University Medical Center have examined the success of more than 13,575 minimally invasive procedures on the mitral valve in the largest study of their kind to date. Key findings: Although patients grew older during the period from 2011 to 2015 and the number of procedures increased from year to year, mortality and complication rates remained consistently low. Mitral valve insufficiency is the most common heart valve disease in Europe and the USA. About ten percent of people over the age of 75 are affected. The patients suffer from a weak closure and thus a leaky mitral valve. Until a few years ago, there was often only the possibility of a drug therapy, because for an open operation, the patients are usually too old, have too many comorbidities or the function of the left ventricle is too bad. There is now a new option to treat this leaky heart valve minimally invasive with a Mitraclip implantation. Germany is one of the leading nations in this innovative, new process. "Several studies with small groups of patients have already been published for the evaluation of the procedure with regard to frequency of inserting the clip or the safety of the procedure, however, so far there have been no large data collections", explain the first and last authors of the study Dr. Ralph Stephan von Bardeleben, Dr. Lukas Hobohm and Dr. Karsten Keller. "That’s why it was a good idea to examine the implantation numbers and the complication rates in Germany on a larger scale." Their results show: The annual implantation numbers in Germany increased more than fivefold from 815 in 2011 to 4,432 in 2015. In total, the study included 13,575 patients who had been treated with Mitraclip. Earlier studies referred to a maximum of 1,064 procedures. The patients were usually between 70 and 89 years old and on average they got older and older. Another important result is that the complication rate or mortality did not change significantly during the period studied. Important prognostic factors related to hospital death were cardiac insufficiency, blood transfusion due to bleeding complications, stroke, pulmonary embolism, or pericardial effusion. The authors conclude from their findings that despite the dramatic fivefold increase in the implantation rate of the clip, the procedure has very low early-stage complication rates during hospitalization. "Catheter-assisted valvular heart valve therapy has evolved from a niche treatment of inoperable patients into a relevant and safe treatment option in only ten years, as our new study emphasizes once again", underlines Dr. von Bardeleben. The Mainz University Medical Center occupies a leading position in the field of gentle heart valve therapy, both nationally and internationally. "In 2018, we implanted more than 700 heart valves, making us one of the largest university centers for minimally invasive heart valve therapy," explains Professor Dr. Thomas Münzel, Director of Cardiology I at the Center for Cardiology of the Mainz University Medical Center. "There were more than 200 Mitraclips. This number is unique in the world.” Cardiologists have also taken the opportunity to establish a new Heart Valve Unit in Mainz because of a striking increase in demand for such interventions in recent years. The advantage of the new heart valve unit: All relevant steps in the course of a heart valve implantation – from patient admission to planning and aftercare on the intensive care unit until to the discharge of patients – take place at one ward. Mainz University Medical Centerhttps://tinyurl.com/y4y75dvs
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:49Study confirms treatment success in minimally invasive Mitral Valve Surgery
Women have unique risk factors for heart disease that need to be taken into account in prevention and treatment strategies, according to a Cleveland Clinic cardiologist who led a team tasked with updating recommendations on women and cardiovascular disease for the American College of Cardiology.
Traditionally, doctors have treated men and women as the same when it comes to heart disease, but the director of the Women’s Cardiovascular Center at Cleveland Clinic, Leslie Cho, M.D., says that it is time to start thinking differently.
She explains: “For years, we’ve thought about men and women as having the exact same risk factors, namely, high blood pressure, hyperlipidemia, smoking, diabetes and family history. However, while heart disease is the number-one killer and most prevalent disease in women, women actually have very low risk in terms of the traditional risk factors.
“However, some conditions specific to women, such as endometriosis, have been found to raise the risk of developing coronary artery disease – the leading cause of heart attacks – by 400% in women under age 40.”
In compiling the updated recommendations, Dr. Cho and her team reviewed diseases that are more prevalent in women; sex-related differences in traditional risk factors; and risk factors that only women experience, such as those related to pregnancy. Risks unique to women In terms of pregnancy-related conditions, they noted that high blood pressure during pregnancy, gestational diabetes, preterm birth and miscarriages all increase a woman’s risk of developing heart disease. Identification of pregnancy-related conditions is important, says Dr Cho, as it can help identify younger women, with low traditional-risk scores, to allow for earlier monitoring of cardiometabolic factors and management.
Hormonal conditions specific to women have also been associated with increased heart risk. One of these is premature menopause, defined as menopause before the age of 40.
Dr Cho explains: “Estrogen offers women some protection from heart disease until after menopause, when estrogen levels drop. This is why the average age of for a heart attack in women is later, at 70, as opposed to 66 in men.”
Another sex-specific risk factor is a hormonal condition called polycystic ovarian syndrome (POCS), found in one in 10 women. This is associated with cardiometabolic factors, which, in turn, are associated with increased heart disease risk. The cardiometabolic factors associated with POCS include abdominal obesity, abnormal glucose control and diabetes, elevated blood pressure, and abnormal amounts of fats – such as cholesterol – in the blood, known as dyslipidemia. Differences in traditional risks Regarding sex-related differences in the traditional risk-factor category, it has been found that hypertension and diabetes are strong risk factors in women. Another risk factor, high blood pressure, is more common in women over the age of 50 than in men.
Woman are also more likely than men to experience depression or mental health issues, such as anxiety and chronic emotional stress, that can have an impact on their heart health.
“We really should be treating not just the blood pressure number, or the cholesterol number, but rather treating the whole patient, including their mental health, to have a good cardiovascular outcome,” says Dr. Cho.
She adds that studies have also shown sex differences in response to treatments, and doctors need to take these into account. Common prevention strategies Despite the different sex-related risks, Dr. Cho points out that there are common areas where either sex can lower their risk for heart disease by making changes to their lifestyles. Among these she includes avoiding smoking, getting regular exercise – at least a 30-minute walk daily – and maintaining normal weight, blood pressure, blood lipid and blood sugar levels. She recommends a diet high in fruits, vegetables, whole grains and fish, and low in animal products, simple carbohydrates and processed foods.
https://interhospi.com/wp-content/uploads/sites/3/2020/08/CCF_Dr_Leslie_Cho-scaled.jpg256020483wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:30Cleveland Clinic advises different approach to preventing CVD in women
For the benefit of healthcare professionals, medical researchers and the public, Elsevier has created a Novel Coronavirus Information Center with free information in English and Mandarin on the novel coronavirus 2019-nCoV.
The information center on Elsevier Connect, the company’s public news and information website, brings together relevant content from Elsevier’s medical journals, textbooks, clinical experts and information solutions, along with resources from other information providers and major health organizations.
Also available is information typically used by practicing nurses and doctors, plus resources designed specifically for patients and their families.
“As a member of the research and health community, we want to support healthcare professionals, clinical researchers and policy makers in understanding how this new virus works, and so we have brought together the best available information in this free, one-stop information centre,” said John Danaher, MD, President, Global Clinical Solutions, Elsevier. “This site aligns with Elsevier’s commitment to provide free access to key medical and scientific research and information for patients and their caregivers.”
Elsevier’s Novel Coronavirus Information Center is curated by a group of clinicians and other experts at Elsevier, and will be updated frequently with the most current research and evidence-based information available.
The information centre on Elsevier Connect will be updated continuously. The site also links to other authoritative resources, including the US Centers for Disease Control and Prevention (CDC) and the WHO. Sites for health authorities in other affected countries are also listed.
Visit Elsevier’s Novel Coronavirus Information Center — https://www.elsevier.com/connect/coronavirus-information-center
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:34Elsevier creates free Covid-19 information centre
As the COVID-19 pandemic upends life as people know it, changing daily routines, limiting social interactions and shaking their sense of safety, a mental health experts from U.S. hospital Cleveland Clinic’s Mellen Center is stressing that it is perfectly acceptable to feel sad about all of it.
She points out that grief is a natural response to loss – whether it is the loss of a loved one, or the loss of a sense of normalcy.
“We are experiencing a lot of disappointment right now – in both small and big ways – and grief is going to be a factor,” says clinical health psychologist Amy Sullivan, PsyD, ABPP.
“It’s really important that we process this and stay connected to other people in safe ways,” she adds.
Regarding how people should go about dealing with all of these difficult and unexpected feelings bubbling up, she says there is no right or wrong way. However, she offers four suggestions that can help people to cope with current events. 1. Look through the lens of grief and process emotions
She says that the stages of grief can provide a helpful framework for navigating these complex emotions. Experts recognize these stages as denial, anger, bargaining, despair, and acceptance. However, these experts also know that people do not step neatly from one stage to the next in this exact order, she says.
“Grief can come in waves and change on a very regular basis. Our feelings can change on a daily, or even an hourly, basis,” she explains.
Dr. Sullivan adds it is normal to go from feeling despair one day to anger the next.
“The first thing we need to do is to recognize that it is normal to have these waves of emotions that are happening on a regular basis,” Dr. Sullivan says.
Next, she says, acknowledge the loss whether it is knowing or losing someone with COVID-19, losing jobs, missing friends or family.
“Those are all very sad, difficult things for people to manage,” Dr. Sullivan says.
“Feel what you are feeling – whether it is being overwhelmed, anxious, powerless or anything else, it can help to identify and name these emotions,” she advises.
“It can be quite powerful to sit with those feelings for a few moments – to really recognize those emotions and normalize them,” she says.
However, she advises people to set a time limit on this, suggesting they give themselves five minutes to feel that emotion, and then move on to something that they know is a positive coping skill for them.
“It is important for us to accept where our feelings are at the moment and process through them, and then move into a more positive position of acceptance,” she says.
She says this can be done by identifying their own best coping mechanisms
“This is a time when people need to become innovative and develop their own individual sense of coping that works for them during this time,” she says. Examples might include deep breathing, mindfulness exercises, journaling, talking with another person, or going for a walk.
“If it comes to a point where someone cannot handle these feelings on their own, they need to seek mental health help,” Dr. Sullivan says. 2. Fight the urge to disengage
Dr. Sullivan stresses that staying connected is a powerful tool for coping during hard times. Whether that comes in the form of video chatting or sending a good old-fashioned letter, staying in touch with family, friends, neighbours and coworkers can help people to keep a positive attitude, she says.
She adds that many trained mental and behavioural health professionals are currently seeing patients through virtual visits, so that if people are having trouble coping, this could be a solution. 3. Focus on what can be controlled
Dr. Sullivan says that when there is so much uncertainty about the future, it is easy for people to get carried away, playing out the worst-case scenarios in their heads, for example worrying about themselves or someone else getting COVID-19, or wondering if things will ever get back to normal.
“Anticipating negative events can bring a sense of anxiety or fear,” Dr. Sullivan says.
She advises that, instead of agonizing over the things that cannot be known or controlled, people should be aware of what they do have control over. For example, they can choose how much news or social media they consume in a day, and they can decide what they eat. She recommends being mindful about these choices, and focusing on staying in the present. 4. Be open to joy
Lastly, Dr. Sullivan advises people to find joy and gratitude in the small things, like a video chat with family members, or the rush of fresh air when they open a window or step outside. She adds that if they are under a lockdown order, they can find ways to appreciate the opportunity to step back from the hustle and bustle of everyday life and being home.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:37Mental health expert urges people to accept grief and other feelings amid COVID-19 pandemic
GAMBICA is the Trade Association for Instrumentation, Control, Automation and Laboratory Technology in the UK. Our insight and influence help our members to be more competitive by increasing their knowledge and impact. Together we remove barriers and maximise the market potential in our industry. GAMBICA members are active in the following sectors: • Industrial automation products and systems • Process instrumentation and control • Laboratory technology • Test and measurement equipment for electrical and electronics industries
www.gambica.org.uk
Medica booth # 1G01-3
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:41GAMBICA at Medica
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.